<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of poorly controlled or breakthrough chemotherapy-induced nausea and vomiting in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of poorly controlled or breakthrough chemotherapy-induced nausea and vomiting in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of poorly controlled or breakthrough chemotherapy-induced nausea and vomiting in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul J Hesketh, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3368009127"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Few side effects of cancer treatment are more feared by patients than nausea and vomiting. Although nausea and emesis (vomiting and/or retching) can result from surgery or radiation therapy, chemotherapy-induced nausea and vomiting (CINV) is potentially the most severe and most distressing.</p><p>The objective of prophylactic antiemetic therapy is the complete prevention of CINV, and this should be achievable in the majority of patients receiving chemotherapy, even with highly emetogenic agents. However, many patients experience clinically significant CINV (poorly controlled or "breakthrough" CINV) despite the use of guideline-directed, appropriate prophylaxis. For these patients, immediate treatment with additional antiemetics is indicated, followed by a reassessment of the adequacy of the prophylactic regimen.</p><p>Management of poorly controlled or breakthrough CINV will be reviewed here. Prevention of CINV in adult patients receiving cancer chemotherapy is reviewed separately as is the pathophysiology of CINV, the characteristics of antiemetic drugs, and nausea and vomiting associated with radiation therapy and opioid analgesics. (See  <a class="medical medical_review" href="/d/html/1150.html" rel="external">"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting"</a> and  <a class="medical medical_review" href="/d/html/2538.html" rel="external">"Characteristics of antiemetic drugs"</a> and  <a class="medical medical_review" href="/d/html/7052.html" rel="external">"Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment"</a> and  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain", section on 'Nausea and vomiting'</a>.)</p><p class="headingAnchor" id="H3536749968"><span class="h1">PROPHYLAXIS FOR CINV</span><span class="headingEndMark"> — </span>Antiemetics are most effective when given prophylactically, and it is preferable to use maximally effective antiemetics as first-line therapy rather than withholding them for later use at the time of antiemetic failure (ie, breakthrough or poorly controlled CINV) [<a href="#rid1">1</a>]. Guidelines for prophylactic antiemetic therapy for intravenously administered chemotherapy according to the estimated risk of CINV are available from the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network, and in a year 2016 update of recommendations from the Multinational Association of Supportive Care in Cancer (MASCC)/European Society for Medical Oncology (ESMO) [<a href="#rid1">1-4</a>]. Our approach to prophylaxis, which largely parallels recommendations from MASCC/ESMO and ASCO, is summarized in the following sections and outlined in the accompanying table  (<a class="graphic graphic_table graphicRef72865" href="/d/graphic/72865.html" rel="external">table 1</a>).</p><p>Despite the use of guideline-directed, appropriate antiemetic prophylaxis, as many as 30 to 40 percent of patients experience clinically significant CINV, particularly those individuals receiving highly emetogenic chemotherapy regimens (eg, those containing <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or a combination of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>). Delayed nausea is a particular problem, since conventional antiemetics are more successful at preventing emesis than at preventing nausea, particularly delayed nausea.</p><p>Prevention of CINV is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults"</a>.)</p><p class="headingAnchor" id="H3118548660"><span class="h1">MANAGEMENT OF POORLY CONTROLLED AND BREAKTHROUGH CINV</span></p><p class="headingAnchor" id="H500713287"><span class="h2">Initial evaluation</span><span class="headingEndMark"> — </span>For patients with breakthrough CINV, clinicians should reevaluate disease status, concurrent illnesses and medications, the emetic risk of the chemotherapy regimen, and ascertain that the best regimen was administered for that regimen.</p><p>Examples of other disease- and medication-related causes for emesis include:</p><p class="bulletIndent1"><span class="glyph">●</span>The use of opioid analgesics (see  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain", section on 'Nausea and vomiting'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Certain antibiotics (eg, <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a>), and infectious causes (see  <a class="medical medical_review" href="/d/html/2537.html" rel="external">"Approach to the adult with nausea and vomiting", section on 'Acute disorders'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system metastases (see  <a class="medical medical_review" href="/d/html/5217.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of brain metastases", section on 'Clinical manifestations'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal obstruction (see  <a class="medical medical_review" href="/d/html/85393.html" rel="external">"Palliative care of bowel obstruction in cancer patients"</a> and  <a class="medical medical_review" href="/d/html/8037.html" rel="external">"Etiologies, clinical manifestations, and diagnosis of mechanical small bowel obstruction in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastroparesis (see  <a class="medical medical_review" href="/d/html/2640.html" rel="external">"Gastroparesis: Etiology, clinical manifestations, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypercalcemia (see  <a class="medical medical_review" href="/d/html/832.html" rel="external">"Clinical manifestations of hypercalcemia"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abdominopelvic radiation therapy (see  <a class="medical medical_review" href="/d/html/7054.html" rel="external">"Overview of gastrointestinal toxicity of radiation therapy"</a> and  <a class="medical medical_review" href="/d/html/7052.html" rel="external">"Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment"</a>)</p><p></p><p>Assuming that other disease and medication-related issues are excluded, it is important to ensure that the patient received the antiemetic regimen appropriate for the drug(s) being given  (<a class="graphic graphic_table graphicRef58756" href="/d/graphic/58756.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef65923" href="/d/graphic/65923.html" rel="external">table 3</a>) at the correct dose and schedule  (<a class="graphic graphic_table graphicRef72865" href="/d/graphic/72865.html" rel="external">table 1</a>). As an example, if the recommended prophylactic regimen included a glucocorticoid on days 2 to 4 to prevent delayed emesis, and it was not administered, it should be given. (See  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults", section on 'Prevention of delayed emesis'</a>.)</p><p class="headingAnchor" id="H236064435"><span class="h2">Treatment</span></p><p class="headingAnchor" id="H41337503"><span class="h3">Olanzapine</span><span class="headingEndMark"> — </span>For most patients who experience nausea or vomiting despite optimal prophylaxis for CINV and who did not receive <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> with the initial prophylactic regimen, we suggest olanzapine rather than a different rescue antiemetic, in addition to continuing the standard antiemetic regimen. The use of a 5 mg rather than 10 mg dosing regimen may reduce treatment-related sedation.</p><p><a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">Olanzapine</a> is a second-generation antipsychotic that blocks serotonin type two 5-hydroxytryptamine (5-HT2) receptors and dopamine D2 receptors. Olanzapine is an effective rescue emetic for refractory CINV, achieving complete control of nausea and emesis in 50 to 70 percent of patients [<a href="#rid5">5,6</a>]. In the only published randomized trial conducted in patients receiving standard dose chemotherapy, superiority for olanzapine (10 mg orally, daily for three days) over <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a> (10 mg orally, three times daily for three days) for treatment of breakthrough nausea and vomiting was shown in a double-blind randomized trial involving 80 patients receiving highly emetogenic chemotherapy [<a href="#rid7">7</a>]. During the 72-hour observation period, significantly more patients receiving olanzapine had no recurrent emesis (70 versus 31 percent) and no nausea (68 versus 23 percent). Fewer than 2 percent of patients receiving olanzapine reported sedation on days 1 or 3. There were no grade 3 or 4 adverse effects in either group, and symptom scores, such as sedation, did not differ significantly.</p><p>The optimal dose for <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> is not definitively established. We generally prefer the 5 mg dose, at least initially, to diminish the likelihood of treatment-related somnolence. A year 2018 review of olanzapine for CINV prophylaxis concluded that there is insufficient evidence to exclude the possibility that 5 mg doses may confer a lower risk of somnolence or fatigue as compared with 10 mg doses [<a href="#rid8">8</a>]. However, a later randomized phase II trial not included in the analysis concluded that a lower prophylaxis dose (5 mg orally, three times a day for three days) provides similar antiemetic efficacy with a more favorable side effect profile than a 10 mg dose [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults", section on 'Olanzapine'</a>.)</p><p class="headingAnchor" id="H3256537218"><span class="h3">Alternative conventional antiemetics</span><span class="headingEndMark"> — </span>For patients who experience nausea or vomiting despite optimal prophylaxis for CINV and who previously received <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, they may be offered an antiemetic of a different class than was administered with the prophylactic regimen, in addition to continuing the standard antiemetic regimen. Options include a neurokinin-1 receptor (NK1R) antagonist, <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> or <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a>, a dopaminergic antagonist (eg, <a class="drug drug_general" data-topicid="9816" href="/d/drug information/9816.html" rel="external">prochlorperazine</a>, thiethylperazine, <a class="drug drug_general" data-topicid="8516" href="/d/drug information/8516.html" rel="external">haloperidol</a>), or an alternative type of type three 5-hydroxytryptamine (5-HT3) antagonist than was administered initially.</p><p>With the exception of the single trial, described above comparing <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a> with <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a> [<a href="#rid7">7</a>], there are no randomized trials that have investigated or compared the benefits of other conventional antiemetics in the management of breakthrough CINV, and the literature on benefit from specific strategies is sparse. (See <a class="local">'Olanzapine'</a> above.)</p><p>Older agents that were previously used for prevention of CINV have generally not been formally studied for the treatment of established CINV in the context of modern prophylactic regimens that include a 5-HT3 antagonist plus <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> with or without a NK1R antagonist.</p><p>Scattered case reports and small series support benefit for <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> [<a href="#rid10">10</a>], <a class="drug drug_general" data-topicid="9816" href="/d/drug information/9816.html" rel="external">prochlorperazine</a> [<a href="#rid11">11</a>], a 5-HT3 antagonist [<a href="#rid11">11,12</a>], a transdermal topical gel containing lorazepam, <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> and <a class="drug drug_general" data-topicid="8516" href="/d/drug information/8516.html" rel="external">haloperidol</a> [<a href="#rid13">13</a>], NK1R antagonists [<a href="#rid14">14,15</a>], and <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a> plus <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> [<a href="#rid16">16</a>]. There are no data on the use of single-agent glucocorticoids in this setting.</p><p>Consensus-based guidelines from expert groups do not generally provide specific actionable recommendations for rescue medications:</p><p class="bulletIndent1"><span class="glyph">●</span>Multinational Association of Supportive Care in Cancer (MASCC)/European Society for Medical Oncology (ESMO) guidelines suggest that when breakthrough emesis occurs, the prophylactic regimen for subsequent cycles should be changed by switching to a different 5-HT3 antagonist, substituting <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a> for the 5-HT3 receptor antagonist, or adding other agents such as dopamine antagonists or benzodiazepines, but they do not provide a specific recommendation for treating breakthrough CINV [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Year 2020 guidelines from American Society of Clinical Oncology (ASCO) suggest that adults who experience nausea and/or vomiting despite optimal prophylaxis and who have already used <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> may be offered a NK1R antagonist, <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> or <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a>, a dopaminergic antagonist (eg, <a class="drug drug_general" data-topicid="9816" href="/d/drug information/9816.html" rel="external">prochlorperazine</a>, thiethylperazine, <a class="drug drug_general" data-topicid="8516" href="/d/drug information/8516.html" rel="external">haloperidol</a>), or an alternative type of 5-HT3 antagonist than was administered initially [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The National Comprehensive Cancer Network (NCCN) guidelines suggest treating breakthrough CINV with an agent from a drug class that was not used in the prophylactic regimen and recommend continuing the breakthrough medication with subsequent courses of chemotherapy if nausea and vomiting is controlled [<a href="#rid4">4</a>].</p><p></p><p class="headingAnchor" id="H3168667197"><span class="h3">Cannabinoids and medical marijuana</span><span class="headingEndMark"> — </span>Cannabinoids such as <a class="drug drug_general" data-topicid="9394" href="/d/drug information/9394.html" rel="external">dronabinol</a> and <a class="drug drug_general" data-topicid="9995" href="/d/drug information/9995.html" rel="external">nabilone</a> (where available) are an option for rescue antiemetics in patients with refractory nausea and vomiting, but the modest benefits are counterbalanced by an unfavorable side effect profile, especially in older patients. We do not offer use of medical marijuana or cannabidiol (CBD) oil for prevention or treatment of CINV. This recommendation is consistent with published antiemetic guidelines for managing CINV from the NCCN, ASCO, and the MASCC/ESMO, all of which support use of synthetic cannabinoids but not inhaled or ingested marijuana as a rescue antiemetic [<a href="#rid1">1,3,4</a>].</p><p>The potential antiemetic utility of cannabis and cannabinoids was first observed in scattered reports of improved emetic control in patients using marijuana during chemotherapy [<a href="#rid17">17</a>]. Since then, several randomized trials and meta-analyses have addressed the efficacy of synthetic cannabinoids for prevention and management of CINV, but little data on benefit from inhaled or ingested cannabis (medical marijuana).</p><p class="headingAnchor" id="H159983124"><span class="h4">Synthetic cannabinoids</span><span class="headingEndMark"> — </span>Several randomized trials have explored the efficacy of synthetic cannabinoids (versus placebo or other antiemetics) for management of CINV, but none are high-quality controlled clinical trials comparing cannabinoids versus other rescue strategies in patients who are refractory to modern antiemetics. At least five meta-analyses have been conducted addressing benefit of synthetic cannabinoids for management of CINV [<a href="#rid17">17-21</a>]; and a meta-analysis of all five meta-analyses has also been undertaken. A table listing the effect estimates, event rates, and numbers needed to treat from these various analyses is provided  (<a class="graphic graphic_table graphicRef139106" href="/d/graphic/139106.html" rel="external">table 4</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>The 2018 meta-analysis of all five meta-analyses concluded that control of CINV was significantly better with synthetic cannabinoids versus placebo (7 controlled trials, 500 patients, risk ratio [RR] 3.60, 95% CI 2.55-5.09, with a number needed to treat [NNT] of 4), as well as versus other antiemetics (predominantly neuroleptics, 14 trials, 1022 patients, RR 1.85, 95% CI 1.18-2.91, NNT 7) [<a href="#rid22">22</a>]. In a broader analysis that included trials of cannabinoids for managing pain, spasticity, or CINV adverse effects were very common with synthetic cannabinoids, including dizziness (3 trials, 666 patients, RR 2.87, 95% CI 2.02-4.08, 32 versus 11 percent, number needed to harm [NNH] 5), sedation (15 trials, 1373 patients, relative risk 1.66, 95% CI 1.46-1.89, NNH 5), confusion (5 trials, 508 patients, RR 2.85, 95% CI 1.25-6.47, NNH 15), and dissociation (6 trials, 571 patients, RR 8.58, 95% CI 6.38-11.5, NNH 20). "Feeling high" during treatment was reported by 35 to 70 percent of users.</p><p></p><p class="bulletIndent1">Despite these adverse effects, patient preference significantly favored the cannabinoid over both placebo (RR 4.82, 95% CI 1.74-13.36) and other antiemetics (RR 2.76, 95% CI 1.88-4.03) with available data all coming from one of the meta-analyses [<a href="#rid21">21</a>]. The quality of evidence ratings for benefit were modest for the comparison of cannabinoids versus placebo (downgraded because of serious risk of bias and imprecision); all other comparisons were low to very low quality evidence because of risk of bias, inconsistency, and imprecision. However, there was a large magnitude of effect.</p><p></p><p class="bulletIndent1">Although concern about the abuse potential of cannabinoid drugs has slowed their development, a few synthetic cannabinoid-type drugs are commercially available, and others are under study. Guidelines from the NCCN, ASCO, and MASCC/ESMO [<a href="#rid3">3,4</a>] all state that cannabinoids such as <a class="drug drug_general" data-topicid="9394" href="/d/drug information/9394.html" rel="external">dronabinol</a> can be considered for refractory nausea and vomiting, and as a rescue antiemetic.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9394" href="/d/drug information/9394.html" rel="external">Dronabinol</a> is approved in the United States for CINV in patients who have failed to respond adequately to conventional antiemetic treatments. In Canada and the UK, another oral cannabinoid (<a class="drug drug_general" data-topicid="9995" href="/d/drug information/9995.html" rel="external">nabilone</a>) is available, but this was discontinued in the United States in 2019. An oromucosal spray containing THC plus CBD (and smaller concentrations of other compounds), called <a class="drug drug_general" data-topicid="9457" href="/d/drug information/9457.html" rel="external">nabiximols</a> (Sativex), is also approved in Canada and elsewhere (but not yet in the United States) for treatment of neuropathic pain due to multiple sclerosis, but not refractory nausea and vomiting. However, it has been used off label for this purpose. It is rapidly absorbed from the buccal mucosa, and the dose can be self-titrated by the patient.</p><p></p><p class="headingAnchor" id="H2798702628"><span class="h4">Medical marijuana</span><span class="headingEndMark"> — </span>Although one of the most common reasons for patients to request access to medical marijuana is to relieve refractory nausea and vomiting [<a href="#rid23">23</a>], its value for the prevention and treatment of CINV remains uncertain. An early prospective, uncontrolled pilot study from 1988 found that inhaled cannabis was effective in 78 percent of 56 patients who had inadequate control of CINV with the conventional antiemetics that were available at that time [<a href="#rid24">24</a>], but there have been no subsequent clinical reports addressing efficacy of inhaled or ingested marijuana for CINV.</p><p>Medical use of smoked, vaporized, or ingested cannabis ("medical marijuana") is legal in several countries, including the Netherlands and Canada. Cannabis use is still illegal in the United States at the federal level (which considers marijuana a schedule I controlled substance) but is legal in most states. Clinicians may not prescribe cannabis but the states that have legalized medical use may rely on clinician assessment to determine eligibility for treatment and recommended formulation and dose.</p><p class="bulletIndent1">Given the heterogeneous legal status of marijuana, especially within the United States, the differences in cannabinoid concentrations across strains of cannabis and available products [<a href="#rid25">25</a>], the inability to stipulate, know, or titrate the dose taken by the patient, the general paucity of evidence-based information about efficacy for CINV, and concerns about respiratory effects and cancer risk in cannabis smokers [<a href="#rid26">26-32</a>], we do not offer medical marijuana to patients with refractory CINV, even in jurisdictions where it is legal. However, given the state of the science and the sociopolitical complexities, each clinician must make his or her own decision about this issue while hopefully keeping an open mind. In jurisdictions where it is legal, should patients experience refractory CINV or report using and benefitting from medical marijuana, it is reasonable to accept a patient's decision to try <a class="drug drug_general" data-topicid="134930" href="/d/drug information/134930.html" rel="external">medical cannabis</a> and continue its use if it is helpful.</p><p></p><p class="headingAnchor" id="H2034296790"><span class="h4">CBD oil</span><span class="headingEndMark"> — </span>CBD (cannabidiol) is a naturally occurring molecule which is derived from cannabis but lacks tetrahydrocannabinol (THC) and thus has no psychoactive properties. It can be procured by patients from legal marijuana dispensaries, online companies, or street suppliers (CBD oil [nutraceutical]). An approved formulation of CBD oil (pharmaceutical) is now available in the United States as a purified product available by prescription (Epidiolex) and approved for treatment of some types of refractory epilepsy in children. (See  <a class="medical medical_review" href="/d/html/108722.html" rel="external">"Dravet syndrome: Management and prognosis"</a> and  <a class="medical medical_review" href="/d/html/138854.html" rel="external">"Lennox-Gastaut syndrome"</a>.)</p><p>Although CBD oil (herbal) is used by patients as a nutraceutical for a variety of other conditions, there are few data on its benefits or risks in cancer patients, and use cannot be recommended. A single phase II randomized, double-blind, placebo-controlled trial of CBD oil for relief of symptoms in advanced cancer concluded that CBD oil did not add value to the reduction in symptom distress (including nausea and vomiting) provided by specialist palliative care [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H2931686032"><span class="h3">Complementary therapies</span><span class="headingEndMark"> — </span>For patients with CINV despite an adequate prophylactic regimen, there is insufficient evidence for a recommendation either for or against the use of ginger supplementation, acupuncture/acupressure, or other complementary therapies. However, given the low potential for harm, a trial of ginger supplementation or acupuncture/acupressure is reasonable for patients who desire it.</p><p class="headingAnchor" id="H3672977073"><span class="h4">Ginger</span><span class="headingEndMark"> — </span>Conventional antiemetics are more successful at preventing emesis than at preventing nausea. At least eight randomized placebo-controlled trials have studied the benefit of ginger (Zingiber officinale) as an aid to reduce nausea during chemotherapy, with mixed results. Five demonstrate at least some benefit [<a href="#rid34">34-38</a>], while three did not [<a href="#rid39">39-41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The largest trial randomly assigned 744 patients who experienced nausea following any chemotherapy cycle despite the use of a prophylactic antiemetic regimen to placebo or supplemental ginger (at doses of 0.5, 1, or 1.5 g twice daily) for six days, starting three days prior to the first day of the next two chemotherapy cycles [<a href="#rid34">34</a>]. All patients received a 5-HT3 receptor antagonist on day 1 of all cycles. Two-thirds of the enrolled patients were receiving chemotherapy for breast cancer. All doses of ginger were associated with a significant reduction in acute nausea throughout day 1 of the chemotherapy cycles, although the largest reduction was seen with the 0.5 and 1 g doses. The authors concluded that ginger supplementation significantly aids in reduction of day 1 nausea during chemotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, in contrast to these results, a benefit for ginger in addition to conventional antiemetics (5-HT3 antagonists and/or <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a>) could not be shown in a randomized placebo-controlled phase II trial of 162 cancer patients who had suffered CINV during at least one prior cycle of chemotherapy [<a href="#rid39">39</a>]. In fact, patients who took ginger plus aprepitant had more severe acute nausea than did those who took only aprepitant.</p><p></p><p>Updated 2020 guidelines from ASCO state that the evidence is insufficient for a recommendation for or against use of ginger to prevent CINV [<a href="#rid3">3</a>]. On the other hand, in 2018, ASCO endorsed the Society for Integrative Oncology (SIO) evidence-based guideline for the use of integrative therapies after breast cancer treatment, stating that ginger could be considered as an addition to standard antiemetic drugs to control nausea and vomiting during chemotherapy [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H3391742188"><span class="h4">Acupuncture and related therapies</span><span class="headingEndMark"> — </span>Several techniques have been used to stimulate the pericardium 6 (P6 or Neiguan) site, which is commonly thought to be useful in the management of CINV. These include manual stimulation with the insertion of fine needles (acupuncture), acupuncture using electrical stimulation (electroacupuncture), and noninvasive pressure on the skin over the P6 pressure point (ie, acupressure).</p><p>Multiple trials have explored the benefits of acupuncture and acupressure for control of CINV [<a href="#rid43">43-47</a>]. Unfortunately, interpretation of the results of randomized trials is hampered by a high risk of bias in most studies and a lack of a control group undergoing a sham procedure in most, lack of standardization of treatment methods, and comparison groups that do not reflect modern antiemetic therapy. A year 2013 systematic review of acupuncture in cancer care included 11 randomized trials in which nausea and vomiting were assessed; eight were considered to have a high risk of bias [<a href="#rid48">48</a>]. Only one trial [<a href="#rid43">43</a>] had a low risk of bias and demonstrated a short-term benefit for electroacupuncture after chemotherapy for breast cancer. The authors concluded that, based upon the single positive study with a low risk of bias, acupuncture could be considered an appropriate adjunctive treatment for management of CINV but that additional studies were needed.</p><p>Even if there are benefits, they are likely to be modest:</p><p class="bulletIndent1"><span class="glyph">●</span>In one multicenter randomized sham-controlled trial, the addition of acupuncture to standard antiemetics for prevention of CINV did not improve the proportion of patients with a complete control of CINV at any time point (from day 1 through day 21), but it did modestly reduce the severity of both nausea and vomiting [<a href="#rid49">49</a>]. Treatment was overall well-tolerated, and there were no adverse events in either group in the study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another trial, in which 500 patients receiving chemotherapy were randomly assigned to acupressure wrist bands, a sham acupressure control group, or conventional antiemetic care, there were no statistically significant differences among all three arms as regards to control of nausea, vomiting, or quality of life, although the median nausea scores for the four cycles of chemotherapy were somewhat lower in both the real and sham acupressure groups [<a href="#rid46">46</a>]. Furthermore, qualitatively, patients perceived the wristbands (both real and sham) to be as effective and helpful in the management of their chemotherapy-related nausea. These data suggest a strong placebo-effect, as has been seen in other trials utilizing these approaches in a variety of settings. (See  <a class="medical medical_review" href="/d/html/1390.html" rel="external">"Overview of the clinical uses of acupuncture", section on 'Research challenges'</a>.)</p><p></p><p>Consensus-based guidelines are discordant:</p><p class="bulletIndent1"><span class="glyph">●</span>Updated 2020 antiemetic guidelines from ASCO state that the evidence is insufficient for a recommendation for or against use of acupuncture/acupressure to prevent CINV [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, in the 2018 endorsement of the SIO guideline for the use of integrative therapies after breast cancer treatment, ASCO stated that acupressure and electroacupuncture could each be considered as an addition to antiemetic drugs to control nausea and vomiting during chemotherapy [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NCCN guidelines suggest consideration of acupuncture/acupressure as an alternative treatment approach for anticipatory CINV only [<a href="#rid4">4</a>].</p><p></p><p class="headingAnchor" id="H2634271647"><span class="h4">Other nonpharmacologic complementary/integrative medicine strategies</span><span class="headingEndMark"> — </span>Findings from randomized controlled trials of reasonable quality provide limited support for several nonpharmacologic complementary/integrative therapy approaches to reduce CINV, including cognitive distraction (eg, playing video games during treatment), systematic desensitization (a cognitive approach using visualization and learned relaxation techniques), exercise, massage, hypnosis, progressive muscle relaxation, yoga, and transcutaneous electrical nerve stimulation [<a href="#rid50">50-55</a>]. (See  <a class="medical medical_review" href="/d/html/2831.html" rel="external">"Overview of complementary, alternative, and integrative medicine practices in oncology care, and potential risks and harm"</a>.)</p><p>Updated 2020 guidelines from ASCO and the joint ASCO/SIO guideline on integrative therapies for patients with breast cancer both state that the evidence is insufficient for a recommendation for or against use of any of these complementary/integrative therapies to prevent or treat CINV [<a href="#rid3">3,42,56</a>].</p><p class="headingAnchor" id="H3108838811"><span class="h2">Managing subsequent cycles of chemotherapy</span><span class="headingEndMark"> — </span>Once the breakthrough emesis has been controlled, attention must be paid to modifying the prophylactic regimen to be used for subsequent chemotherapy courses, if continuation of the same regimen is planned.</p><p>The majority of patients who have breakthrough emesis have derived some benefit from the original antiemetic regimen employed. Thus, the original antiemetic regimens should usually be retained, and other agents added.</p><p>Options for modifying the prophylactic antiemetic regimen include:</p><p class="bulletIndent1"><span class="glyph">●</span>If the chemotherapy regimen was categorized as moderate risk (eg, a non-carboplatin-containing regimen), the prophylactic regimen can be adjusted to one that is typically used for a higher risk group (ie, with the addition of a NK1R antagonist)  (<a class="graphic graphic_table graphicRef72865" href="/d/graphic/72865.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults", section on 'Recommendations for specific groups'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If it was not given initially, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> can be added to the prophylactic regimen. (See  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults", section on 'Olanzapine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient previously received <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, the addition of an agent from a different drug class is reasonable and supported by NCCN guidelines [<a href="#rid4">4</a>]. The choice of agent should be based on assessment of the current prevention strategies used. Some patients may require several agents utilizing differing mechanisms of action.</p><p></p><p class="bulletIndent1">Options include <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> or <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a>, or a dopaminergic antagonist (eg, <a class="drug drug_general" data-topicid="9816" href="/d/drug information/9816.html" rel="external">prochlorperazine</a>, thiethylperazine, <a class="drug drug_general" data-topicid="8516" href="/d/drug information/8516.html" rel="external">haloperidol</a>), or substituting high-dose intravenous <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a> for the 5-HT3 antagonist [<a href="#rid3">3,57</a>]. (See <a class="local">'Alternative conventional antiemetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another alternative is to switch to a different 5-HT3 antagonist since there may be incomplete cross-resistance between agents [<a href="#rid58">58-61</a>]. This approach was tested in a double-blind trial in which patients who failed <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a> plus <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> in the first 24 hours following highly emetogenic chemotherapy were randomly assigned to continue the same treatment or switch to <a class="drug drug_general" data-topicid="8501" href="/d/drug information/8501.html" rel="external">granisetron</a> plus dexamethasone. There was a significantly higher rate of complete protection from emesis in the patients who switched to granisetron (47 versus 5 percent) [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If anxiety is a major factor in the refractory CINV, the addition of a benzodiazepine may be particularly helpful. (See  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults", section on 'Anticipatory emesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If patients desire nonpharmacologic therapy, a trial of acupuncture/acupressure is reasonable although benefits appear modest, at best. (See <a class="local">'Acupuncture and related therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If patients desire a trial of a cannabinoid, such an approach is also reasonable. One placebo-controlled randomized phase II trial that used a crossover design examined the efficacy of adding an oral mixture of THC plus CBD to <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, a 5HT3 receptor antagonist, and an NK1R antagonist for subsequent cycles of chemotherapy in 81 patients with poorly controlled emesis after the first cycle [<a href="#rid62">62</a>]. Efficacy was modest (complete response rates improved from 14 to 25 percent, but 72 percent of the patients in the cannabinoid arm required rescue with conventional antiemetics, and 31 percent still vomited), and 31 percent experienced moderate or severe cannabis-related adverse effects, including sedation, dizziness, and disorientation. Despite this, patient preference after the crossover phase overwhelmingly favored the cannabinoid (83 versus 15 percent). A randomized phase III trial is planned. (See <a class="local">'Cannabinoids and medical marijuana'</a> above.)</p><p></p><p class="bulletIndent1">As noted above, we do not offer medical marijuana or CBD oil for either prophylaxis or treatment of CINV.</p><p></p><p class="headingAnchor" id="H1036080249"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116116.html" rel="external">"Society guideline links: Chemotherapy-induced nausea and vomiting in adults"</a>.)</p><p class="headingAnchor" id="H2359538011"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16303.html" rel="external">"Patient education: Nausea and vomiting with cancer treatment (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1270744707"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – For patients presenting with poorly controlled or breakthrough chemotherapy-induced nausea and vomiting (CINV), clinicians should reevaluate disease status, concurrent illnesses and medications, the predicted emetic risk of the chemotherapy regimen, and ascertain that the appropriate and best prophylactic regimen was administered for that regimen. (See <a class="local">'Initial evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiemetic treatment</strong> – If an otherwise treatable cause is not identified, adding an appropriate antiemetic therapy to the initial prophylactic regimen is appropriate.</p><p></p><p class="bulletIndent1">For most patients we suggest <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> rather than a different rescue antiemetic, in addition to continuing the standard antiemetic regimen (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The use of a 5 mg rather than 10 mg dosing regimen may reduce treatment-related sedation. (See <a class="local">'Olanzapine'</a> above.)</p><p></p><p class="bulletIndent1">Alternatives to <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> are appropriate, particularly if the patient had been previously treated with olanzapine. Options include a neurokinin-1 receptor antagonist, <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> or <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a>, a dopaminergic antagonist (eg, <a class="drug drug_general" data-topicid="9816" href="/d/drug information/9816.html" rel="external">prochlorperazine</a>, thiethylperazine, <a class="drug drug_general" data-topicid="8516" href="/d/drug information/8516.html" rel="external">haloperidol</a>), or an alternative type of 5-hydroxytryptamine (5-HT3) antagonist than was administered initially. (See <a class="local">'Alternative conventional antiemetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of other therapies</strong> – We do not offer use of medical marijuana or cannabidiol (CBD) oil for prevention or treatment of CINV. However, cannabinoids such as <a class="drug drug_general" data-topicid="9394" href="/d/drug information/9394.html" rel="external">dronabinol</a> and <a class="drug drug_general" data-topicid="9995" href="/d/drug information/9995.html" rel="external">nabilone</a> (where available) are an option for rescue antiemetics; their modest efficacy must be counterbalanced by the risk for side effects, particularly in older adults. (See <a class="local">'Cannabinoids and medical marijuana'</a> above.)</p><p></p><p class="bulletIndent1">For patients with CINV despite an adequate prophylactic regimen, there is insufficient evidence for a recommendation either for or against the use of ginger supplementation, acupuncture/acupressure, or other complementary therapies. However, these modalities have low potential for harm, and a trial of these approaches is reasonable for patients who desire it. (See <a class="local">'Complementary therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent cycles of chemotherapy</strong> – Once the breakthrough emesis has been controlled, future prophylactic regimens for subsequent chemotherapy courses should be modified if the same chemotherapy regimen is to be continued. Several strategies may be considered, based upon clinician and patient preference, and are outlined above. (See <a class="local">'Managing subsequent cycles of chemotherapy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27:v119.</a></li><li><a class="nounderline abstract_t">Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017; 35:3240.</a></li><li><a class="nounderline abstract_t">Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020; 38:2782.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Chanthawong S, Subongkot S, Sookprasert A. Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting. J Med Assoc Thai 2014; 97:349.</a></li><li><a class="nounderline abstract_t">Vig S, Seibert L, Green MR. Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity. J Cancer Res Clin Oncol 2014; 140:77.</a></li><li><a class="nounderline abstract_t">Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2013; 21:1655.</a></li><li><a class="nounderline abstract_t">Sutherland A, Naessens K, Plugge E, et al. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev 2018; 9:CD012555.</a></li><li><a class="nounderline abstract_t">Yanai T, Iwasa S, Hashimoto H, et al. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 2018; 23:382.</a></li><li><a class="nounderline abstract_t">Mughal TI. Improved tolerance of cytotoxic chemotherapy with lorazepam. A pilot study. Oncology 1983; 40:392.</a></li><li><a class="nounderline abstract_t">Jones JM, Qin R, Bardia A, et al. Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. J Palliat Med 2011; 14:810.</a></li><li><a class="nounderline abstract_t">Mitchell PL, Evans BD, Allan SG, et al. Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics. N Z Med J 1992; 105:73.</a></li><li><a class="nounderline abstract_t">Bleicher J, Bhaskara A, Huyck T, et al. Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials. J Support Oncol 2008; 6:27.</a></li><li><a class="nounderline abstract_t">Osorio-Sanchez JA, Karapetis C, Koczwara B. Efficacy of aprepitant in management of chemotherapy-induced nausea and vomiting. Intern Med J 2007; 37:247.</a></li><li><a class="nounderline abstract_t">Oechsle K, Müller MR, Hartmann JT, et al. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone. Onkologie 2006; 29:557.</a></li><li><a class="nounderline abstract_t">Mori K, Saito Y, Tominaga K. Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone. Double-blind randomized crossover study in patients with cisplatin-induced emesis. Am J Clin Oncol 1993; 16:338.</a></li><li><a class="nounderline abstract_t">Smith LA, Azariah F, Lavender VT, et al. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 2015; :CD009464.</a></li><li><a class="nounderline abstract_t">Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA 2015; 313:2456.</a></li><li><a class="nounderline abstract_t">Machado Rocha FC, Stéfano SC, De Cássia Haiek R, et al. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) 2008; 17:431.</a></li><li><a class="nounderline abstract_t">Mücke M, Carter C, Cuhls H, et al. [Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety]. Schmerz 2016; 30:25.</a></li><li><a class="nounderline abstract_t">Tramèr MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323:16.</a></li><li><a class="nounderline abstract_t">Allan GM, Finley CR, Ton J, et al. Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms. Can Fam Physician 2018; 64:e78.</a></li><li><a class="nounderline abstract_t">Vinette B, Côté J, El-Akhras A, et al. Routes of administration, reasons for use, and approved indications of medical cannabis in oncology: a scoping review. BMC Cancer 2022; 22:319.</a></li><li><a class="nounderline abstract_t">Vinciguerra V, Moore T, Brennan E. Inhalation marijuana as an antiemetic for cancer chemotherapy. N Y State J Med 1988; 88:525.</a></li><li><a class="nounderline abstract_t">Bonn-Miller MO, Loflin MJE, Thomas BF, et al. Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA 2017; 318:1708.</a></li><li><a class="nounderline abstract_t">Bowles DW, O'Bryant CL, Camidge DR, Jimeno A. The intersection between cannabis and cancer in the United States. Crit Rev Oncol Hematol 2012; 83:1.</a></li><li><a class="nounderline abstract_t">Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med 2014; 370:2219.</a></li><li><a class="nounderline abstract_t">Owen KP, Sutter ME, Albertson TE. Marijuana: respiratory tract effects. Clin Rev Allergy Immunol 2014; 46:65.</a></li><li><a class="nounderline abstract_t">Patel S, Williams JW Jr, Wallace RB. What We Do (and Don't) Know About the Health Effects of Cannabis and Whether Marijuana Is Medicine. Ann Intern Med 2017; 166:747.</a></li><li><a class="nounderline abstract_t">Ghasemiesfe M, Ravi D, Vali M, et al. Marijuana Use, Respiratory Symptoms, and Pulmonary Function: A Systematic Review and Meta-analysis. Ann Intern Med 2018; 169:106.</a></li><li class="breakAll">The National Academies of Science, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. 2017. https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state (Accessed on May 10, 2021).</li><li><a class="nounderline abstract_t">Incze MA, Kelley AT, Singer PM. Heterogeneous State Cannabis Policies: Potential Implications for Patients and Health Care Professionals. JAMA 2021; 326:2363.</a></li><li><a class="nounderline abstract_t">Hardy J, Greer R, Huggett G, et al. Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD). J Clin Oncol 2023; 41:1444.</a></li><li><a class="nounderline abstract_t">Ryan JL, Heckler CE, Roscoe JA, et al. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer 2012; 20:1479.</a></li><li><a class="nounderline abstract_t">Pillai AK, Sharma KK, Gupta YK, Bakhshi S. Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatr Blood Cancer 2011; 56:234.</a></li><li><a class="nounderline abstract_t">Panahi Y, Saadat A, Sahebkar A, et al. Effect of ginger on acute and delayed chemotherapy-induced nausea and vomiting: a pilot, randomized, open-label clinical trial. Integr Cancer Ther 2012; 11:204.</a></li><li><a class="nounderline abstract_t">Uthaipaisanwong A, Oranratanaphan S, Musigavong N. Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study. Support Care Cancer 2020; 28:3831.</a></li><li><a class="nounderline abstract_t">Arslan M, Ozdemir L. Oral intake of ginger for chemotherapy-induced nausea and vomiting among women with breast cancer. Clin J Oncol Nurs 2015; 19:E92.</a></li><li><a class="nounderline abstract_t">Zick SM, Ruffin MT, Lee J, et al. Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer 2009; 17:563.</a></li><li><a class="nounderline abstract_t">Fahimi F, Khodadad K, Amini S, et al. Evaluating the effect of zingiber officinalis on nausea and vomiting in patients receiving Cisplatin based regimens. Iran J Pharm Res 2011; 10:379.</a></li><li><a class="nounderline abstract_t">Bossi P, Cortinovis D, Fatigoni S, et al. A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin. Ann Oncol 2017; 28:2547.</a></li><li><a class="nounderline abstract_t">Lyman GH, Greenlee H, Bohlke K, et al. Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. J Clin Oncol 2018; 36:2647.</a></li><li><a class="nounderline abstract_t">Shen J, Wenger N, Glaspy J, et al. Electroacupuncture for control of myeloablative chemotherapy-induced emesis: A randomized controlled trial. JAMA 2000; 284:2755.</a></li><li><a class="nounderline abstract_t">Ezzo JM, Richardson MA, Vickers A, et al. Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. Cochrane Database Syst Rev 2006; :CD002285.</a></li><li><a class="nounderline abstract_t">Roscoe JA, Matteson SE, Morrow GR, et al. Acustimulation wrist bands are not effective for the control of chemotherapy-induced nausea in women with breast cancer. J Pain Symptom Manage 2005; 29:376.</a></li><li><a class="nounderline abstract_t">Molassiotis A, Russell W, Hughes J, et al. The effectiveness and cost-effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: Assessment of Nausea in Chemotherapy Research (ANCHoR), a randomised controlled trial. Health Technol Assess 2013; 17:1.</a></li><li><a class="nounderline abstract_t">Dibble SL, Luce J, Cooper BA, et al. Acupressure for chemotherapy-induced nausea and vomiting: a randomized clinical trial. Oncol Nurs Forum 2007; 34:813.</a></li><li><a class="nounderline abstract_t">Garcia MK, McQuade J, Haddad R, et al. Systematic review of acupuncture in cancer care: a synthesis of the evidence. J Clin Oncol 2013; 31:952.</a></li><li><a class="nounderline abstract_t">Li QW, Yu MW, Wang XM, et al. Efficacy of acupuncture in the prevention and treatment of chemotherapy-induced nausea and vomiting in patients with advanced cancer: a multi-center, single-blind, randomized, sham-controlled clinical research. Chin Med 2020; 15:57.</a></li><li><a class="nounderline abstract_t">Lotfi-Jam K, Carey M, Jefford M, et al. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol 2008; 26:5618.</a></li><li><a class="nounderline abstract_t">Tian X, Tang RY, Xu LL, et al. Progressive muscle relaxation is effective in preventing and alleviating of chemotherapy-induced nausea and vomiting among cancer patients: a systematic review of six randomized controlled trials. Support Care Cancer 2020; 28:4051.</a></li><li><a class="nounderline abstract_t">Molassiotis A, Yung HP, Yam BM, et al. The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomised controlled trial. Support Care Cancer 2002; 10:237.</a></li><li><a class="nounderline abstract_t">Yoo HJ, Ahn SH, Kim SB, et al. Efficacy of progressive muscle relaxation training and guided imagery in reducing chemotherapy side effects in patients with breast cancer and in improving their quality of life. Support Care Cancer 2005; 13:826.</a></li><li><a class="nounderline abstract_t">Raghavendra RM, Nagarathna R, Nagendra HR, et al. Effects of an integrated yoga programme on chemotherapy-induced nausea and emesis in breast cancer patients. Eur J Cancer Care (Engl) 2007; 16:462.</a></li><li><a class="nounderline abstract_t">Billhult A, Bergbom I, Stener-Victorin E. Massage relieves nausea in women with breast cancer who are undergoing chemotherapy. J Altern Complement Med 2007; 13:53.</a></li><li><a class="nounderline abstract_t">Greenlee H, DuPont-Reyes MJ, Balneaves LG, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin 2017; 67:194.</a></li><li><a class="nounderline abstract_t">Einhorn LH, Rapoport B, Navari RM, et al. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 2017; 25:303.</a></li><li><a class="nounderline abstract_t">de Wit R, de Boer AC, vd Linden GH, et al. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer 2001; 85:1099.</a></li><li><a class="nounderline abstract_t">Harousseau JL, Zittoun R, Bonneterre J, et al. [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination]. Bull Cancer 2000; 87:491.</a></li><li><a class="nounderline abstract_t">Sigsgaard T, Herrstedt J, Christensen P, et al. Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy. Support Care Cancer 2000; 8:233.</a></li><li><a class="nounderline abstract_t">Hulstaert F, Van Belle S, Bleiberg H, et al. Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting. J Clin Oncol 1994; 12:2439.</a></li><li><a class="nounderline abstract_t">Grimison P, Mersiades A, Kirby A, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol 2020; 31:1553.</a></li></ol></div><div id="topicVersionRevision">Topic 134925 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27664248" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28759346" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32658626" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Antiemetics: ASCO Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32658626" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antiemetics: ASCO Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25123016" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24173694" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23314603" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30246876" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29039073" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6646606" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Improved tolerance of cytotoxic chemotherapy with lorazepam. A pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21554125" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1532054" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18257398" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17388865" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy of aprepitant in management of chemotherapy-induced nausea and vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17202825" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8392288" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone. Double-blind randomized crossover study in patients with cisplatin-induced emesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26561338" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26103030" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cannabinoids for medical use: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18625004" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26809975" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : [Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11440936" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29449262" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35331185" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Routes of administration, reasons for use, and approved indications of medical cannabis in oncology: a scoping review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3231372" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Inhalation marijuana as an antiemetic for cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29114823" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Labeling Accuracy of Cannabidiol Extracts Sold Online.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22019199" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The intersection between cannabis and cancer in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24897085" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Adverse health effects of marijuana use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23715638" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Marijuana: respiratory tract effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28384665" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : What We Do (and Don't) Know About the Health Effects of Cannabis and Whether Marijuana Is Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29971337" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Marijuana Use, Respiratory Symptoms, and Pulmonary Function: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29971337" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Marijuana Use, Respiratory Symptoms, and Pulmonary Function: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34797377" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Heterogeneous State Cannabis Policies: Potential Implications for Patients and Health Care Professionals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36409969" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21818642" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20842754" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22313739" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effect of ginger on acute and delayed chemotherapy-induced nausea and vomiting: a pilot, randomized, open-label clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31834519" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26414587" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Oral intake of ginger for chemotherapy-induced nausea and vomiting among women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19005687" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24250368" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Evaluating the effect of zingiber officinalis on nausea and vomiting in patients receiving Cisplatin based regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28666335" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29889605" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11105182" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Electroacupuncture for control of myeloablative chemotherapy-induced emesis: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625560" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15857741" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Acustimulation wrist bands are not effective for the control of chemotherapy-induced nausea in women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23803562" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The effectiveness and cost-effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: Assessment of Nausea in Chemotherapy Research (ANCHoR), a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17723973" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Acupressure for chemotherapy-induced nausea and vomiting: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23341529" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Systematic review of acupuncture in cancer care: a synthesis of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32514290" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy of acupuncture in the prevention and treatment of chemotherapy-induced nausea and vomiting in patients with advanced cancer: a multi-center, single-blind, randomized, sham-controlled clinical research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981466" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32346796" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Progressive muscle relaxation is effective in preventing and alleviating of chemotherapy-induced nausea and vomiting among cancer patients: a systematic review of six randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904789" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15856335" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Efficacy of progressive muscle relaxation training and guided imagery in reducing chemotherapy side effects in patients with breast cancer and in improving their quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17944760" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effects of an integrated yoga programme on chemotherapy-induced nausea and emesis in breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17309378" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Massage relieves nausea in women with breast cancer who are undergoing chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28436999" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27815710" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11710819" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10903790" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10789966" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7964961" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32801017" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
